Overview

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Status:
COMPLETED

Trial end date:
2025-02-24

Target enrollment:

Participant gender:

Summary

The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity.

Phase:

PHASE1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

BI 456906